Open access
Oct 2026
Real‐World Characteristics and Early Outcomes of Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Carcinoma
Enfortumab vedotin (EV) plus pembrolizumab (EVP) has become a standard first‐line regimen for unresectable locally advanced or metastatic urothelial carcinoma. Further characterization of clinical heterogeneity and toxicity may complement existing Japanese real‐world data.
T. Tsujino, K. Tamura, R. Taoka et al.
· International journal of uro... · 0 citations